Author

David A. Burt

Observed names: Burt DA, D Burt, D. Burt, David A Burt, David Burt

Institution: Trevena, Inc. (United States)

Observed institutions: Hartford Hospital, University of Connecticut, Abbott (United States), Bristol-Myers Squibb (United States), Lotus Clinical Research, Premier Research Group, Wyeth, Trevena, Inc. (United States), The University of Texas Medical Branch at Galveston

ORCID: 0000-0002-3432-1377

Observed ORCID: 0000-0002-3432-1377

OpenAlex ID: A5103016296

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine ( TRV 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty

2019 · Neil K. Singla, Franck Skobieranda, et al. · Pain Practice · 184

PDF

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

2019 · Eugene R Viscusi, Franck Skobieranda, et al. · Journal of Pain Research · 167

PDF

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

2017 · Neil Singla, Harold Minkowitz, et al. · Journal of Pain Research · 152

PDF

Oliceridine (TRV130), a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model

2018 · Michael J. Fossler, Brian M. Sadler, et al. · The Journal of Clinical Pharmacology · 43

Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain

2020 · Sabry Ayad, Mark A. Demitrack, et al. · Clinical Drug Investigation · 40

PDF

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

2019 · Anne N. Nafziger, Kelly A. Arscott, et al. · Clinical Pharmacology in Drug Development · 40

PDF

Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans

2013 · Alan G. Japp, Raj Chelliah, et al. · Journal of the American Heart Association · 32

PDF

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects

2006 · Linda E. Gustavson, Sarah M. Schweitzer, et al. · Clinical Therapeutics · 23

Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects

2013 · G Tong, I Savant, et al. · The Journal of Headache and Pain · 22

PDF

Oliceridine, a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model

2018 · Michael J. Fossler, Brian M. Sadler, et al. · The Journal of Clinical Pharmacology · 13

Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836

2014 · Ming Zheng, Lieuwe Appel, et al. · Psychopharmacology · 12

(432) Respiratory safety signal with oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), vs morphine: a safety analysis of a Phase 2b randomized clinical trial

2016 · N. Singla, H. Minkowitz, et al. · Journal of Pain · 8

PDF

(223) APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel μ receptor G protein Pathway Selective (μ-GPS) modulator, for management of moderate to severe acute pain following bunionectomy

2017 · F. Skobieranda, N. Singla, et al. · Journal of Pain · 5

APOLLO-1: a Randomized, Controlled, Phase 3 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Pain Following Bunionectomy

2017 · Neil K. Singla, Anthony Senagore, et al. · The Spine Journal · 4

Comparison of different QT interval correction methods for heart rate and QT beat‐to‐beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS‐820836

2015 · Ming Zheng, David Burt, et al. · The Journal of Clinical Pharmacology · 4

(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trials

2016 · E. Viscusi, H. Minkowitz, et al. · Journal of Pain · 2

(435) Nausea and vomiting with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs morphine: an analysis of tolerability from a phase 2b randomized clinical trial

2016 · H. Minkowitz, N. Singla, et al. · Journal of Pain · 2

Gastrointestinal Tolerability With Oliceridine, A Novel µ Receptor G Protein Pathway Selective (µ-GPS) Modulator [4H]

2017 · Adam C. Steinberg, David Soergel, et al. · Obstetrics and Gynecology · 1

I2. Rapid Onset of Pain Relief with Oliceridine (TRV130) vs. Morphine: a Phase 2a/b Study Analysis

2017 · David Soergel, Eugene Viscusi, et al. · Pain Management Nursing · 1

Effect of atrasentan (ABT-627, ATN) on the pharmacokinetics (PK) of midazolam (MDZ)

2004 · J. Z. Peng, T. Doan, et al. · Journal of Clinical Oncology · 1

2017 · Singla N, Minkowitz HS, et al. · Dove Medical Press (Taylor and Francis Group)

PDF

I1. A Randomized, Placebo- and Active-Controlled Phase 2b Study Investigating Oliceridine (TRV130)

2017 · David Soergel, Harold Minkowitz, et al. · Pain Management Nursing

Dose Interruptions with Morphine vs Oliceridine (TRV130), a Novel μ Receptor G Protein Pathway Selective (μ-GPS) Modulator: Analysis from a Placebo- and Morphine-Controlled Phase 2b Study in Patients Following Abdominoplasty

2016 · Anthony J. Senagore, David Soergel, et al. · Journal of the American College of Surgeons

(343) Oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. II: simulation of potential dosing regimens using a pharmacokinetic/pharmacodynamic (PK/PD) model

2016 · M. Fossler, B. Sadler, et al. · Journal of Pain

PDF

(342) Oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic (PK/PD) model

2016 · M. Fossler, B. Sadler, et al. · Journal of Pain

PDF

Works count: 26

Citation count: 756

H-index: 11

I10-index: 11